CClinicalTrials.gg
RecruitingNCT04832113ETADAPTUpdated Aug 31, 2023

Impact of Patient's Therapeutic Education in APA and Dietetic on Radiotherapy Reproducibility Sessions for Prostate Cancer

An interventional study of Adapted Physical Activity and Dietetic and conventional management in Prostate Cancer, sponsored by Centre Leon Berard. Recruiting at 5 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Centre Leon Berard · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The primary objective of this study is to evaluate the impact of Patient's Therapeutic Education (PTE) in Adapted Physical Activity (APA) ans dietetic on the reduction of interventions number on rectal volume (laxative or probe).

The secondary objectives are to evaluate the contribution of Patient's Therapeutic Education (PTE) between the 2 arms on repositionnind during the radiotherapy session, the gastrointestinal toxicity, the need to use laxative or transit regulating treatment or techniques, the quality of life, the undernutrition and food intake, the evolution in eating/hydratation and physical habits.

For the experimetal arm, the satisfaction and the compliance with PTE program will be evaluated, as well as the need of additionnal use of dietary and APA consultations.

Read the detailed description

Prostate cancer is the 3rd cause of cancer mortality in patient aged over 50 years. Radiotherapy treatment plans require specific conditions:

  • Reproductibility of patient's positioning (requiring management of bladder and rectal fillings at each session).
  • An image-guided treatment consisting in acquiring an image before each session. This pre-treatment Imaging allows the optimal adjustment of the target volume and organs at risk (bladder and rectum).

To allow reproductibility of target volume positioning at each radiotherapy session, it's recommended to have an empty rectum at the time of the radiotherapy preparation scan, and to check repletion before each session.

It's recommended that the patient has a comfortably full bladder to limit the volume of irradiated bladder mucosa. The radiotherapy teams don't have any recommendations concerning the rectum and manage this problem session by session, according to the repositioning Imaging of the current day.

According to a pilot study carried out in 2017 in the radiotherapy department of the Léon Bérard center, an intervention for a dilated rectum (probe or laxative) was necessary for an average of 25% of session per patient.

These rectal problems can be partly explained by the age (60-80 years) and sedentary lifestyle of patients with prostate cancer. Physical activities, adapted hydratation and changes in eating habits are an integral part of the constipation and flatulence prevention.

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's planned enrollment of 216 is above the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Centre Leon Berard is the lead sponsor of 206 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

I1: Age >= 18 years old.

I2: Patient with prostatic adenocarcinoma with indication for first-line or post-operative radiotherapy (adjuvant or biologic recurrence).

I3: Patient able to practice a physical activity (certificate of aptitude for adapted physical activity).

I4: Life expectancy greater than 6 months.

I5: Absence of chronic inflammatory intestinal disease or intestinal surgery.

I6: Signed informed consent.

I7: Patient covered by a medical insurance.

I8. At least 20 sessions of radiotherapy planned

Exclusion criteria

Exclusion Criteria:

E1: Patient does not understand and cannot read French.

E2: Patient followed for a psychiatric pathology or presenting cognitive disorders.

E3: Inability to comply with study follow-up goegraphical, social or psychological reasons.

E4: Patient requiring tutorship or curatorship or patient deprived of liberty.

E5: Participation to another clinical trial which may interfere with principal Endpoint assessment.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    Patient Therapeutics Education (PTE)

    Educational diagnosis prior radiotherapy and participation to Patient Therapeutics Education (PTE) in Adapted Physical Activity (APA) and dietetic sessions. In addition to conventional support (dietary and hydration advice).

    Other: Adapted Physical Activity and Dietetic

  • Other
    Conventional support

    Dietary and hydration advices

    Other: conventional management

Interventions

  • OtherAdapted Physical Activity and Dietetic

    session in addtion conventional management dietetic, hydratation and physical activity

    Also known as: Follow-up of Adapted Physical Activity and Dietetic Hydratation

  • Otherconventional management

    Dietary and hydratation advices according to the recommendations

    Also known as: conventional management dietary and hydratation

06

What researchers measure

Primary outcomes

  1. Evaluate the impact of Patient's Therapeutic Education in APA on the reduction of interventions number on rectum

    Number of uninstallation during the radiotherapy session

    Time frame: An average of 4 months

Secondary outcomes

  1. Evaluate the contribution of Patient's Therapeutic Education on patient's repositionning efficiency

    Rate of patients never uninstalled compared to patients uninstalled during prostate's radiotherapy

    Time frame: An average of 4 months

  2. Evaluate the contribution of Patient's Therapeutic Education on the gastrointestinal toxicity

    Acute gastrointestinal toxicity ≥ grade 2 (NCI- CTCAE V5)

    Time frame: An average of 4 months

  3. Evaluate the contribution of Patient's Therapeutic Education on the use of laxative or transit regulating treatment or techniques

    Prescribed laxatives or transit regulation treatments or techniques

    Time frame: An average of 4 months

  4. Evaluate the contribution of Patient's Therapeutic Education on patients' quality of life

    Using European Organisation for Research and Treatment of Cancer - Core Quality of life questionnaire (QLQC30) (Evaluation of patient's quality of life during the last 7 days - From 4 \[worse reply\] to 1 \[better reply\])

    Time frame: An average of 4 months

  5. Evaluate the contribution of Patient's Therapeutic Education on the undernutrition

    Collection of patients' weight (kg)

    Time frame: An average of 4 months

  6. Evaluate the contribution of Patient's Therapeutic Education on the food intake

    Collection of patients' weight (kg)

    Time frame: An average of 4 months

  7. Evaluate the contribution of Patient's Therapeutic Education on the undernutrition

    Using Socio Economic Factor Index scale (SEFI) (Scale from 10 \[I ate my entire meal\] to 0 \[I did not eat anything\])

    Time frame: An average of 4 months

  8. Evaluate the contribution of Patient's Therapeutic Education on the food intake

    Using Socio Economic Factor Index scale (SEFI) (Scale from 10 \[I ate my entire meal\] to 0 \[I did not eat anything\])

    Time frame: An average of 4 months

  9. Evaluate the contribution of Patient's Therapeutic Education on the undernutrition

    Using the "Eating and hydration habits questionnaire"

    Time frame: An average of 4 months

  10. Evaluate the contribution of Patient's Therapeutic Education on the food intake

    Using the "Eating and hydration habits questionnaire"

    Time frame: An average of 4 months

  11. Evaluate the contribution of Patient's Therapeutic Education on the evolution in eating habits

    Using the "Eating and hydration habits questionnaire"

    Time frame: An average of 4 months

  12. Evaluate the contribution of Patient's Therapeutic Education on the evolution in hydratation habits

    Using the "Eating and hydration habits questionnaire"

    Time frame: An average of 4 months

  13. Evaluate the contribution of Patient's Therapeutic Education on the evolution in APA habits

    Using International Physical Activity Questionnaire (IPAQ) (Description of the physical activity during the last 7 days)

    Time frame: An average of 4 months

  14. Evaluate patient's satisfaction with Patient's Therapeutic Education program (experimental arm)

    Using satisfaction questionnaire (scale from 1 \[worse evaluation\] to 4 \[better evaluation\])

    Time frame: An average of 4 months

  15. Evaluate the compliance to APA session recommendations

    Daily collection of steps numbers

    Time frame: An average of 4 months

  16. Evaluate the compliance to APA session recommendations

    Evaluation during phone calls every 15 days

    Time frame: An average of 4 months

  17. Evaluate the number of patients requiring additional dietetic session

    Evaluation during phone calls every 15 days

    Time frame: An average of 4 months

  18. Evaluate the number of patients requiring additional APA session

    Evaluation during phone calls every 15 days

    Time frame: An average of 4 months

07

Study locations

2 of 5 sites recruiting
  • Chu de saint etienne
    Saint-Étienne, Rhône-Alpes Auvergne 42000, France
    Not yet recruiting
  • Groupe Hospitalier Mutualiste de Grenoble Institut Daniel HOLLARD
    Grenoble, 38028, France
    Recruiting
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
    Not yet recruiting
  • Centre Eugène Marquis
    Rennes, 35042, France
    Recruiting
  • Institut de Cancérologie de l'Ouest René Gauducheau
    Saint-Herblain, 44805, France
    Not yet recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04832113
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Apr 5, 2021
Start date
Jun 21, 2021
Primary completion
Oct 2024 (estimated)
Completion
Apr 2025 (estimated)
Last update
Aug 31, 2023

Study contacts

Séverine METZGER
Contact
severine.metzger@lyon.unicancer.fr
+33478782786
Pascale Roux
Contact
pascale.roux@lyon.unicancer.fr
+33478787200
Pascale Roux
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion